Strategic Investors Sanguina recently secured a strategic investment round from Georgia-based partners including Emory BioFoundry Institute, Invest Georgia, and Georgia Tech Research Impact Fund, signaling strong regional support and potential introductions to health systems and research collaborations.

FDA Clearance Advantage With FDA clearance achieved for AnemoCheck Home, Sanguina has a credible regulatory milestone that can ease conversations with payers and health systems seeking validated home health monitoring solutions.

Rapid Recognition RADx Maternal Health Challenge grand prize wins in 2024 and 2025 reinforce credibility in maternal health and may open doors to grant programs, collaborations with maternal care providers, and payer consideration for risk prediction datasets.

B2B Partnerships Existing focus on partnering with healthcare systems, insurers, and industry to generate biomarker datasets presents ongoing opportunities to expand within hospital networks, value-based care programs, and population health initiatives.

Global Data Network The smartphone-based biomarker platform leverages millions of proprietary data points collected globally, enabling scalable blood health insights that can be monetized through data-sharing arrangements with pharma, research consortia, and wellness platforms.